Af­ter pulling IPO plans, Arti­va part­ners with Af­fimed to speed up NK cell ther­a­py com­bo

The rea­son­ing for with­draw­ing its IPO de­sires? Arti­va Bio­ther­a­peu­tics had a dif­fer­ent big plan to share — one that couldn’t be done un­der the con­straints of hav­ing an S-1 on file with the SEC.

De­spite hav­ing filed the pa­per­work for a Nas­daq de­but about 18 months ago, Arti­va CEO Fred Aslan tells End­points News the main rea­son for halt­ing those am­bi­tions was to re­veal the cov­er on a joint de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion pact with Af­fimed to com­bine the biotechs’ ther­a­pies in­to a treat­ment for CD30-pos­i­tive lym­phoma pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER